Not updated yet!
Galapagos is a mid-sized, clinical stage biotechnology company active in discovery and development of small molecule therapies, many of which are based on proprietary disease modifying drug targets in disease areas for which there is a need for safe and effective medicines. Galapagos funds its research through alliance payments from its pharma partners, licensing agreements, and its cash reserves. Selective JAK1 inhibitor GLPG0634, its most advanced program in Phase II in rheumatoid arthritis and Crohn’s disease, is partnered with AbbVie for up to $1.35 billion in milestones and double-digit royalties. Together with its services company Fidelta, Galapagos’ research activities across Europe are successful thanks to our highly motivated staff of 400 employees, a unique technology base, and a strong financial position.